Sakditad Saowapa: A Promising Targeted Option for Leptomeningeal Metastases from Solid Tumors
Sakditad Saowapa, Oncologist at UI Holden Comprehensive Cancer Center, shared a post on X:
“New Phase 2 TUXEDO‑3 trial (Nature Medicine, May 2025):
Patritumab deruxtecan (HER3‑DXd) given q3w to 20 patients with leptomeningeal metastases from solid tumors
- 3‑mo survival: 65% (KM: 69.6%)
- 6‑mo survival: ~59%
- Most patients had stable or improved neuro symptoms and QoL
- No new neuro AEs
Common AEs (any grade):
- Anemia (41%), Nausea (32%),
- Neutropenia (27%), Diarrhea (27%),
- Asthenia (27%), Headache / Thrombocytopenia (23%)
A promising targeted option in a devastating disease.”
Title: Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial
Journal: Nature
Authors: Matthias Preusser, Javier Garde-Noguera, Juan José García-Mosquera, María Gion, Richard Greil, Miriam Arumi, Manuel Ruiz-Borrego, Antonio Llombart-Cussac, María Valero, Javier Cortés, Marta Campolier, José Antonio Guerrero, Paula González-Alonso, Carlos Jiménez-Cortegana, Jose Rodríguez-Morató, Marta Vaz-Batista, Felicitas Oberndorfer, Maximilian Marhold, Anna Sophie Berghoff, Julia Furtner, Thorsten Fuereder, Rupert Bartsch
More posts featuring Sakditad Saowapa on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023